Tag: PAR
Paradigm Biopharmaceuticals advances Zilosul osteoarthritis program, to trial drug in MPS patients
Paradigm Biopharmaceuticals (ASX: PAR) has completed treatment of its Zilosul injectable pentosan polysulfate (iPPS) drug under the US Food and Drug Administration’s expanded access program, while col...
Paradigm doses all trial patients with Zilosul while dodging COVID-19 impact
An experimental treatment for knee osteoarthritis developed by Paradigm Biopharmaceuticals (ASX: PAR), Zilosul, has now been dosed in all ten patients under the FDA approved expanded access – otherwis...
Paradigm Biopharmaceuticals announces first Zilosul patient under FDA approved program
Paradigm Biopharmaceuticals (ASX: PAR) has declared that the first patient has been dosed under the FDA-approved expanded access program (EAP) for Zilosul in the US, with first results expected someti...
Paradigm Biopharmaceuticals gears up for busy year of clinical trials and regulatory submissions in 2020
With progress to secure regulatory approvals underway for its flagship Zilosul treatment, Paradigm Biopharmaceuticals (ASX: PAR) is also gearing up for phase 2/3 clinical trial in the first quarter of...
Regulatory progress means Paradigm Biopharmaceuticals will treat ex-NFL players with Zilosul later this year
Paradigm Biopharmaceuticals (ASX: PAR) has been given the go-ahead by US regulators to treat 10 former NFL players with its pentosan polysulfate sodium (iPPS) drug, otherwise known as Zilosul.
Foll...
Paradigm Biopharmaceuticals looks to alleviate opiate crisis following ‘ground-breaking discovery
Paradigm Biopharmaceuticals (ASX: PAR) claims it has made a “ground-breaking discovery” as part of its ongoing development of pentosan polysulfate sodium (PPS), an antithrombotic agent that reduces jo...
Paradigm Biopharma receives FDA clearance for investigational new osteoarthritis drug
Medical company Paradigm Biopharmaceuticals (ASX: PAR) has received clearance from the US Food and Drug Administration for an investigational new drug (IND) application relating to pentosan polysulfat...
Paradigm Biopharma’s knee osteoarthritis trial shows injectable drug can slow cartilage degradation
Paradigm Biopharmaceuticals (ASX: PAR) has reported a breakthrough in its phase 2 clinical trial of the injectable pentosan polysulfate (iPPS) treatment drug Zilosul, showing it could act as a cartila...
Paradigm submits first investigational new drug application with US FDA
Medical company Paradigm Biopharmaceuticals (ASX: PAR) has set the stage for a speedy entry into the US after filing its first investigational new drug (IND) submission to the US FDA for an “expanded ...
Paradigm Biopharmaceuticals’ iPPS reduces Ross River virus joint pain
Paradigm Biopharmaceuticals (ASX: PAR) has reported reduced disease symptoms during a phase 2a trial using its injectable pentosan polysulfate sodium (iPPS) drug on Ross River virus sufferers.
Of t...
Real world trial of Paradigm Biopharma’s injectable drug reduces osteoarthritic pain by over 50%
A real-world trial using Paradigm Biopharmaceuticals’ (ASX: PAR) injectable pentosan polysulfate (iPPS) treatment has found the drug can provide a reduction in pain of more than 50% in patients with k...
Paradigm Biopharmaceuticals’ iPPS drug reduces bone marrow lesions in hip, knee caps and ankles
As it advances its injectable Pentosan Polysulfate (iPPS) drug towards commercialisation, Paradigm Biopharmaceuticals (ASX: PAR) has noted a clinically meaningful decrease in bone marrow lesions in hi...
Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise
Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS) drug for osteoarthritis of the knee have confirmed improved kne...
International symposium sets scene for Paradigm Biopharmaceuticals’ MPS trial
Paradigm Biopharmaceuticals (ASX: PAR) has set its sights on applying to the US Food and Drug Administration (FDA) to begin a clinical trial for mucopolysaccharidoses (MPS) following a positive round ...
Paradigm Biopharmaceuticals meets primary endpoints in Phase 2b knee osteoarthritis trial
Paradigm Biopharmaceuticals (ASX: PAR) has confirmed the potential of its injectable pentosan polysulfate sodium (iPPS) drug to be “safe and effective” in treating knee osteoarthritis pain after compl...
Paradigm Biopharmaceuticals reasserts osteoarthritis pain reduction results
Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has reasserted its previously published figures relating to pain reduction resulting from its flagship drug treatment Pentosan Polysulfate ...
Paradigm Biopharmaceuticals to deploy iPPS to treat rare joint disease
Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) is continuing to expand the gamut of applications for its proprietary Pentosan Polysulfate Sodium (iPPS) drug by signing an agreement with ...
Australian Government numbs capital expenditure pain for Paradigm Biopharmaceuticals
Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has received a further boost in its mission to bring a potentially industry-leading chronic pain medication to the Australian and US market...
Paradigm’s injectable osteoarthritis drug trial shows major reduction in chronic pain
Australian biotech company Paradigm Pharmaceuticals (ASX: PAR) has reported an average 51.2% reduction in chronic knee pain by a group of osteoarthritis patients being treated with its injectable Pent...
Paradigm Biopharmaceuticals looks to touchdown its osteoarthritis drug in the United States
Paradigm Biopharmaceuticals (ASX: PAR) has struck a strategic partnership with the Pro Players’ Elite Network (PPEN), a US-based retired professional sporting network comprised of over 11,000 retired ...
Paradigm Biopharmaceuticals looks to scale summit of chronic pain reduction
Biotech company Paradigm Biopharmaceuticals (ASX: PAR) continues to make progress on its mission of developing a radical shift in reducing chronic joint pain from osteoarthritis.
With results from ...
